Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sandor Fritsch
Observed name:
Fritsch, Sandor
Institution:
Baxter (Austria)
Observed institutions:
Baxter (Austria),
John Paul II Hospital,
Baxter (United States)
OpenAlex ID:
A5111891037
A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture
2008
·
Hartmut J. Ehrlich
, Markus Müller
, et al.
·
New England Journal of Medicine
·
286
PDF
Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight
2011
·
Sven Björkman
, MyungShin Oh
, et al.
·
Blood
·
225
PDF
Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease
2015
·
Joan C. Gill
, Giancarlo Castaman
, et al.
·
Blood
·
168
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial
2013
·
Nina Wressnigg
, Eva-Maria Pöllabauer
, et al.
·
The Lancet Infectious Diseases
·
116
Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial
2011
·
P Noel Barrett
, Gregory Berezuk
, et al.
·
The Lancet
·
111
Prevention of tick-borne encephalitis by FSME-IMMUN® vaccines: Review of a clinical development programme
2011
·
Alexandra Loew-Baselli
, Eva Maria Poellabauer
, et al.
·
Vaccine
·
81
Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency
2006
·
Joseph A. Church
, Heinz Leibl
, et al.
·
Journal of Clinical Immunology
·
81
Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity
2003
·
Hartmut J. Ehrlich
, Borislava G. Pavlova
, et al.
·
Vaccine
·
69
Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN®0.5 ml in adults aged 18-67 years
2009
·
Alexandra Loew-Baselli
, Eva-Maria Poellabauer
, et al.
·
Human Vaccines
·
67
PDF
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America
2016
·
Daniel Suez
, Mark Stein
, et al.
·
Journal of Clinical Immunology
·
66
PDF
Comparison of immunogenicity and safety between two paediatric TBE vaccines
2010
·
Eva Maria Pöllabauer
, Borislava G. Pavlova
, et al.
·
Vaccine
·
51
A Cell Culture (Vero)–Derived H5N1 Whole‐Virus Vaccine Induces Cross‐Reactive Memory Responses
2009
·
Hartmut J. Ehrlich
, Markus Müller
, et al.
·
The Journal of Infectious Diseases
·
50
Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency
2016
·
Marilyn Manco-Johnson
, Lisa Bomgaars
, et al.
·
Thrombosis and Haemostasis
·
43
Tolerability of modified tick-borne encephalitis vaccine FSME-IMMUN “NEW” in children: results of post-marketing surveillance
2003
·
B Pavlova
, Alexandra Loew-Baselli
, et al.
·
Vaccine
·
38
Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: A randomized trial
2011
·
Gerald Aichinger
, Hartmut J. Ehrlich
, et al.
·
Vaccine
·
37
Clinical development of a Vero cell culture-derived seasonal influenza vaccine
2011
·
Hartmut J. Ehrlich
, Gregory Berezuk
, et al.
·
Vaccine
·
35
Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® Junior
2012
·
Roman Prymula
, Eva Maria Pöllabauer
, et al.
·
Human Vaccines & Immunotherapeutics
·
33
PDF
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming
2012
·
Maikel V.W. van der Velden
, Gerald Aichinger
, et al.
·
Vaccine
·
29
Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccine
2010
·
Eva Maria Pöllabauer
, Sandor Fritsch
, et al.
·
Vaccine
·
27
Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine
2011
·
Paul A. Tambyah
, Annelies Wilder-Smith
, et al.
·
Vaccine
·
23
Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C®) in infants
2013
·
Eva-Maria Poellabauer
, Borislava G. Pavlova
, et al.
·
Vaccine
·
16
PDF
Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine
2012
·
Hartmut J. Ehrlich
, Markus Müller
, et al.
·
Vaccine
·
16
A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory
2012
·
Alexandra Loew-Baselli
, Borislava G. Pavlova
, et al.
·
Vaccine
·
12
Phase I/II Randomized Double-Blind Study of the Safety and Immunogenicity of a Nonadjuvanted Vero Cell Culture-Derived Whole-Virus H9N2 Influenza Vaccine in Healthy Adults
2014
·
Gerald Aichinger
, Barbara Grohmann-Izay
, et al.
·
Clinical and Vaccine Immunology
·
11
Canadian Society of Allergy and Clinical Immunology annual scientific meeting 2016
2017
·
and the Canadian Healthy Infant Longitudinal Development Study Investigators
, Mohammad A. Alsayegh
, et al.
·
Allergy Asthma and Clinical Immunology
·
10
PDF
Show more works
View as search
Works count:
37
Citation count:
1,732
H-index:
20
I10-index:
25
Year
Topic
Type